CN106282138A - Clostridium sardiniense 7 α hydroxysteroid dehydrogenase mutant T145S - Google Patents
Clostridium sardiniense 7 α hydroxysteroid dehydrogenase mutant T145S Download PDFInfo
- Publication number
- CN106282138A CN106282138A CN201610844106.9A CN201610844106A CN106282138A CN 106282138 A CN106282138 A CN 106282138A CN 201610844106 A CN201610844106 A CN 201610844106A CN 106282138 A CN106282138 A CN 106282138A
- Authority
- CN
- China
- Prior art keywords
- hydroxysteroid dehydrogenase
- mutant
- 7alpha
- dehydrogenase mutant
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01159—7-Alpha-hydroxysteroid dehydrogenase (1.1.1.159)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to hydroxysteroid dehydrogenase, it is specifically related to a kind of Clostridium sardiniense 7 α hydroxysteroid dehydrogenase mutant T145S, its aminoacid sequence as shown in SEQ ID NO:2, be aminoacid sequence be that the 145th amino acids of the 7 α hydroxysteroid dehydrogenases of SEQ ID NO:1 is become Ser gained from Thr.This mutant is to substrate TCDCA and NADP+Catalytic efficiency be 4.85 times of wild type, during bioconversion CDCA/TCDCA obtains UDCA/TUDCA, there is huge application potential.
Description
Technical field
The present invention relates to hydroxysteroid dehydrogenase, be specifically related to a kind of Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase
Mutant T145S.
Background technology
The asymmetric reduction of carbonyl is always one of focus of chemical reaction research.Although chemical method has been achieved with at present
Certain achievement, but chemical method often exists, and catalyst type and Limited Number, stereo selectivity be the highest, auxiliary reagent
The shortcoming such as expensive and be not easily recycled.And enzymatic reaction not only has high efficiency, chemo-selective, regioselectivity and also has height
Stereo selectivity.The enzymatic that hydroxysteroid dehydrogenase (Hydroxysteroid dehydrogenase, HSDH) mediates is anti-
Should have the substrate specificity that relatively stringent stereo selectivity is strict with " no ".Such as, as far back as the early 1980s
Scientist just have begun to attempt 7 α that utilize microorganism to produce-, 7 β-HSDH associating epimerisms convert chenodeoxycholic acid
(Chenodeoxycholic acid, CDCA) synthesis ursodesoxycholic acid (Ursodesoxycholic acid, UDCA), conversion
Process is as shown in Figure 1.And resolvase can be with catalyzed combination state bile acid Taurochenodeoxycholic Acid
(Taurochenodeoxycholic acid, TCDCA) is converted into tauroursodeoxycholic acid (Tauroursodeoxycholic
Acid, TUDCA).
The substrate of HSDH is not solely restricted to steroid compound, and document report HSDH can also be catalyzed alkyl and replace monocycle
The carbonyl asymmetric reduction of the materials such as ketone, bicyclo-ketone.The outstanding catalysis quality that HSDH is had determines it and turns at biology
Change field has bigger application potential.But, active higher HSDH variant is that it is applied further at field of bioconversion
Basic guarantee.In recent years, scientific research personnel gradually recognized 7 α-, 7 β-HSDH field of bioconversion had huge should
Use potentiality.At present, in GenBank registration function it has been acknowledged that 7 α-HSDH have 5, they are respectively from
Bacteroides fragilis、Clostridium scindens、Clostridium sordellii、Clostridium
Absonum and Escherichia coli;From Clostridium absonum and Collinsellaaerofaciens 7
β-HSDH gene is the most successfully cloned.The bioconversion system that above-mentioned dual-enzyme coupling builds not only overcomes coenzyme circulation difficulty
Topic, also achieve oxidation, reduce " cooking-pot type " carry out the hydroxyl epimerism in specified chemical region.
The activity of enzyme is relatively low is one of principal element limiting its commercial Application, almost all of native enzyme be required for through
The requirement of commercial Application is can be only achieved after transformation.Wherein, Clostridium sardiniense 7 α-HSDH (Clostridium absonum7 α-
HSDH, CA 7 α-HSDH) there is long research history and wide application prospect.In addition the crystal structure of this enzyme has solved
Analysis, so it is significant to obtain the mutant that catalytic efficiency significantly improves by the way of rationality is transformed.
Summary of the invention
For meeting the demand that above-mentioned field exists, the present invention provides a kind of Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase
Mutant, has higher catalytic efficiency, can be used for the bioconversion of multiple substrate, has huge application valency in the industrial production
Value.
The technical scheme that the present invention is claimed is as follows:
A kind of Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant, it is characterised in that its aminoacid sequence such as SEQ
Shown in ID NO:2, be aminoacid sequence be the 7alpha-Hydroxysteroid dehydrogenase of SEQ ID NO:1 the 145th amino acids by
Thr becomes Ser gained.
Encode the gene of above-mentioned Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant.
Described gene, it is characterised in that its nucleotide sequence is as shown in SEQ ID NO:3.
A kind of expression cassette, it is characterised in that comprise said gene.
A kind of carrier, it is characterised in that comprise said gene or expression cassette.
A kind of reconstitution cell, it is characterised in that comprise said gene or expression cassette or carrier.
A kind of method preparing above-mentioned Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant, it is characterised in that at energy
Enough success induced proteins cultivate above-mentioned reconstitution cell under conditions of expressing and isolated Clostridium sardiniense 7 alpha-hydroxysteroid takes off
Hydrogen enzyme mutant.
A kind of catalyst, it is characterised in that its effective ingredient comprises above-mentioned Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase
Mutant.Described catalyst, it is characterised in that also include and above-mentioned Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant
Enzyme catalysis efficiency can be improved simultaneously when using or increase other reagent of enzyme stability.
A kind of method of carbonyl asymmetric reduction realizing chemical substance, it is characterised in that use above-mentioned Clostridium sardiniense 7
Alpha-hydroxysteroid dehydrogenase mutant or arbitrary above-mentioned catalyst and reaction substrate 15-37 DEG C, under the conditions of pH 6.0-11.0
Carry out catalytic reaction.
First the present invention compares wild type CA 7 α-HSDH with same from primary structure to the many series of strata of higher structure multi-angle
The similarities and differences of source pheron, it is determined that the site affecting CA 7 α-HSDH zymologic property is the 145th amino acids threonine.So
Replaced by codon afterwards and threonine is become serine, and utilize full genome synthetic technology to obtain CA 7 α-HSDH T145S
The gene of mutant.Finally by the GST fusion expression vector the quiding gene engineering bacteria E.coli that build mutant gene
Abduction delivering in BL21, it is thus achieved that CA 7 α-HSDH T145S mutant zymoprotein.By measuring the enzyme under different concentration of substrate
Promote initial velocity of reaction, utilize Michaelis-Menten equation to be calculated CA 7 α-HSDH wild type and the enzyme kinetic analysis of T145S mutant
Parameter.Result shows, T145S mutant is to substrate TCDCA and NADP+Catalytic efficiency be 4.85 times of wild type, this sudden change
Body has huge application potential during bioconversion CDCA/TCDCA obtains UDCA/TUDCA.
The carrier that the present invention provides, can be cloning vehicle, comprise CA 7 α-HSDH T145S mutant gene and plasmid
Other element needed for duplication;Can also be expression vector, comprise CA 7 α-HSDH T145S mutant gene and egg can be made
Other element of white successful expression.In certain embodiments, described expression vector is for inserting CA 7 α-HSDH T145S sudden change
The pGEX-6p-1 carrier of body gene.
The reconstitution cell that the present invention provides, can be the reconstitution cell comprising cloning vehicle, such as E.coli DH5 α, logical
Crossing cultivation cell makes intracellular CA 7 α-HSDH T145S mutant gene replicate;Can also be comprise expression vector thin
Born of the same parents, cultivate cell under suitable condition, such as, add appropriate IPTG, 16 DEG C of induction CA 7 α-HSDH T145S mutants
The expression of albumen.
The present invention provides a kind of catalyst, and its effective ingredient includes CA 7 α-HSDH T145S mutant.Described catalyst
Can also use with other catalyst being suitable for simultaneously, thus improve enzyme catalysis efficiency or first the most laggard in same reaction system
Two kinds of catalytic reactions of row.
The CA 7 α-HSDH T145S mutant of the present invention, 15-37 DEG C, can under the reaction condition of pH 6.0-11.0
Catalysis TCDCA C7Alpha-hydroxy carbonyl asymmetric reduction reaction.Its optimal reactive temperature is 37 DEG C, and optimum pH is 10.5.
Accompanying drawing explanation
Fig. 1 .7 α-, 7 β-HSDH combine conversion CDCA prepare UDCA schematic diagram.
Fig. 2. the SDS-PAGE of Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant T145S;
Wherein, M is protein molecular weight standard (Marker);1 is T145S mutant protein.
The standard curve of Fig. 3 .NADPH;
Wherein, abscissa is the concentration of NADPH solution, and vertical coordinate is the NADPH solution of each concentration light at 340nm
Absorption value.
Detailed description of the invention
The present invention is further described below in conjunction with specific embodiment, it is to be understood that, following embodiment is only used as explaining
And explanation, limit the scope of the present invention never in any form.
Main agents:
PGEX-6p-1 is known carrier, and this laboratory preserves;
E.coli BL21 cell is that this laboratory preserves;
Lysis buffer, prepares and obtains, and the PBS of 10mM pH7.3 contains PMSF 0.1mM, leupeptin Leupeptin
0.5mg/mL;
Glutathione Sepharose 4B, buys from GE Healthcare, article No.: 10223836;
PreScission Protease, buys from GenScript company, article No.: Z02799-100;
BCA test kit, buys from Beyotime company, article No.: P0006;
TCDCA, buys from lark prestige scientific & technical corporation, article No.: 330776;
Biological chemical reagent not specified in following example is this area conventional reagent, commercially available or press
Obtain according to the preparation of this area conventional method.
The preparation of embodiment 1. Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant
1. mutant gene synthesis
Original series: the wild type CA 7 α-HSDH gene order after codon optimized (sees patent CN102827848A
Publication), its nucleotide sequence is as shown in SEQ ID NO:4.
By comparing wild type CA 7 α-HSDH and homology enzyme egg from the many series of strata of the multi-angle of primary structure to higher structure
The white similarities and differences, it is determined that affect the 145th amino acids that site is wild type CA 7 α-HSDH of zymologic property, described aminoacid
For threonine, corresponding nucleotides sequence is classified as 433-435 bit codon.
Codon at the 433-435 of wild type CA 7 α-HSDH gene order is changed to AGT by ACT, by original
Threonine replaces to serine, obtains CA 7 α-HSDH mutant, named CA 7 α-HSDH T145S mutant, its nucleotide
Sequence is as shown in SEQ ID NO:3, and aminoacid sequence is as shown in SEQ ID NO:2.
5 ' the ends in CA 7 α-HSDH T145S mutant gene sequence introduce restriction enzyme site BamHI, and 3 ' ends introduce enzyme action
Site NotI, for inserting pGEX-6p-by double digestion reaction and coupled reaction by CA 7 α-HSDH T145S mutant gene
Corresponding site in 1 carrier, then send Sangon Biotech company carry out full genome synthesis and carry out sequence verification.Sangon
The plasmid of the CA 7 α-HSDHT145S/pGEX-6p-1 that Biotech company directly provides and CA7 α-HSDHT145S/pGEX-6p-
1/DH5 α glycerol stock.
2. the GST of pheron merges heterogenous expression
(1) Plastid transformation E.coli BL21 cell
A.-80 DEG C is taken out BL21 competent cell E.coli place on ice.
B. add expression plasmid pGEX-6p-1/CA 7 α-HSDH T145S2 μ L after purification, place 30min on ice.
C. heat shock 42 DEG C, 90s.
Place 2min the most on ice.
E. recover, add 600 μ L LB culture medium, 37 DEG C, 150rpm, 45min.
F. draw 200 μ L culture medium and coat Amp+In LB plating medium.
G.37 DEG C overnight incubation.
(2) protein expression and purification
A. inoculating in sterile LB medium by strain, the final concentration of 50 μ g/mL of ampicillin, 37 DEG C, 180rpm trains
Support.
B., when OD600 ≈ 0.8, the IPTG of final concentration of 0.2mM, 16 DEG C of overnight induction (12h) are added.8000rpm,
5min collects thalline.
C. add the resuspended thalline of ratio of 30mL Lysis buffer in 1L cultivating system, carrying out ultrasonic bacteria breaking is to clarification.
12000rpm, 20min.Take supernatant.
D. supernatant is combined with Glutathione Sepharose 4B, and the ratio that filler uses is that every liter of cultivating system uses
5mL filler, 4 DEG C combine 2h.The most vertically overturn suspendible.
E. after combining, 500rpm, 5min precipitation filling.Filler rinses 3-5 column volume with 4 DEG C of pre-cooling PBS.
Remove foreign protein.
F. add PreScission Protease enzyme cutting buffering liquid, add PreScission Protease enzyme.
G.4 DEG C enzyme action is overnight.After enzyme action, supernatant is released from chromatographic column.
H. gained sample is carried out SDS-PAGE, identify its molecular size range and purity, BCA test kit test purifying protein
Concentration.
Result is as in figure 2 it is shown, the display T145S mutant solubility expression success of SDS-PAGE testing result, and through one
After step affinity chromatograph, the band of albumen is single.
Embodiment 2.T145S mutant enzyme kinetic analysis parametric measurement
The making of 1.NADPH standard curve
Reaction buffer (50mM Tris-HCl, 200mM NaCl, pH 8.0) is utilized to prepare 0.1,0.2,0.3 and respectively
The NADPH solution of 0.4mM.After returning to zero by above-mentioned blank solvent, the NADPH solution of each concentration is separately added into 2mL cuvette
In, measure absorbance value OD at 340nm340.With the concentration of NADPH solution as abscissa, corresponding absorbance value is vertical coordinate,
Draw standard curve.
Result is as shown in Figure 3, it is thus achieved that standard curve equation be y=2.7868x-0.0002, R2=0.9999.
2. enzyme activity determination
The cuvette of 2mL volume is sequentially added into 958 μ L reaction buffers (50mM Tris-HCl, 200mM NaCl,
PH 8.0), the NADP of 20 μ L 50mM+, the CA 7 α-HSDH T145S mutant (2.46mg/ for preparing of 2 μ L embodiments 1
ML), the substrate TCDCA of 20 μ L 50mM is added after zeroing.During enzyme kinetic analysis data determination, the change model of the final concentration of substrate
Enclose for 0.1-10mM.
In 25 DEG C, at 340nm, record the light Change of absorption in 1min, and calculate product according to the standard curve of NADPH
Growing amount.Double reciprocal by Lineweaver-Burk by Michaelis-Menten equation (formula 1) equal sign two side draw double (formula 2) reciprocal
Graphing method obtains Km、kcat;And by comparing kcat/KmValue weighs the catalytic efficiency change of mutant.
Result is as shown in table 1, and CA 7 α-HSDH T145S mutant catalysis TCDCA is changed into cattle sulphur-7-Ketolithocholsaeure (T-
Efficiency 7-KLCA) is 4.85 times of wild type CA 7 α-HSDH.
The enzyme kinetic analysis parameter of table 1. wild type CA 7 α-HSDH and T145S mutant catalysis TCDCA
Claims (10)
1. a Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant, it is characterised in that its aminoacid sequence such as SEQ ID
Shown in NO:2, be aminoacid sequence be that the 145th amino acids of the 7alpha-Hydroxysteroid dehydrogenase of SEQ ID NO:1 is become by Thr
For Ser gained.
2. the gene of coding Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant described in claim 1.
Gene the most according to claim 2, it is characterised in that its nucleotide sequence is as shown in SEQ ID NO:3.
4. an expression cassette, it is characterised in that comprise the gene described in claim 2.
5. a carrier, it is characterised in that comprise the gene described in claim 2 or the expression cassette described in claim 4.
6. a reconstitution cell, it is characterised in that comprise the gene described in claim 2 or the expression cassette described in claim 4
Or the carrier described in claim 5.
7. the method preparing Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant described in claim 1, its feature
It is, the reconstitution cell described in claim 6 isolated Sadinia can cultivated under conditions of success induced protein expression
Island clostridium 7alpha-Hydroxysteroid dehydrogenase mutant.
8. a catalyst, it is characterised in that its effective ingredient comprises the Clostridium sardiniense 7 Alpha-hydroxy class described in claim 1
Sterin dehydrogenase mutant.
Catalyst the most according to claim 8, it is characterised in that also include and the Clostridium sardiniense 7 described in claim 1
Enzyme catalysis efficiency can be improved simultaneously when alpha-hydroxysteroid dehydrogenase mutant uses or increase other reagent of enzyme stability.
10. the method for the carbonyl asymmetric reduction realizing chemical substance, it is characterised in that use described in claim 1
Catalyst described in Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant or claim 8 or 9 and reaction substrate are at 15-
37 DEG C, carry out catalytic reaction under the conditions of pH 6.0-11.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610844106.9A CN106282138B (en) | 2016-09-22 | 2016-09-22 | Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant T145S |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610844106.9A CN106282138B (en) | 2016-09-22 | 2016-09-22 | Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant T145S |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106282138A true CN106282138A (en) | 2017-01-04 |
CN106282138B CN106282138B (en) | 2019-10-08 |
Family
ID=57712981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610844106.9A Active CN106282138B (en) | 2016-09-22 | 2016-09-22 | Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant T145S |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106282138B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106676079A (en) * | 2017-01-05 | 2017-05-17 | 重庆大学 | Novel 7alpha-hydroxysteroid dehydrogenase gene S1-a-2 |
CN106701708A (en) * | 2017-01-05 | 2017-05-24 | 重庆大学 | New 7alpha-hydroxysteroid dehydrogenase gene Y1-a-1 |
CN106701707A (en) * | 2017-01-05 | 2017-05-24 | 重庆大学 | Gene S1-a-1 of novel 7 alpha-HSDH (hydroxysteroid dehydrogenase) |
CN107058250A (en) * | 2017-01-05 | 2017-08-18 | 重庆大学 | 7 new beta hydroxysteroid dehydrogenase gene Y1 b 1 |
CN107841489A (en) * | 2017-11-14 | 2018-03-27 | 重庆大学 | The α hydroxysteroid dehydrogenase mutant K179M of Clostridium sardiniense 7 |
CN108034643A (en) * | 2017-12-18 | 2018-05-15 | 重庆大学 | 7alpha-Hydroxysteroid dehydrogenase and its encoding gene and application |
CN110387360A (en) * | 2019-06-18 | 2019-10-29 | 华东理工大学 | Hydroxysteroid dehydrogenase and its application in synthesis ursodeoxycholic acid precursors |
CN112725212A (en) * | 2021-01-15 | 2021-04-30 | 江南大学 | Recombinant yeast chassis cell transformation for efficiently converting chenodeoxycholic acid, recombinant strain construction and application |
CN112852652A (en) * | 2021-01-15 | 2021-05-28 | 江南大学 | Recombinant yeast strain for efficiently converting chenodeoxycholic acid to synthesize ursodeoxycholic acid, construction and application |
CN113430183A (en) * | 2021-08-16 | 2021-09-24 | 重庆大学 | Mutants of 7 alpha-hydroxysteroid dehydrogenase St-2-2T15G, T15S and T15A |
CN114250205A (en) * | 2021-12-28 | 2022-03-29 | 宋建芳 | 7 alpha-hydroxysteroid dehydrogenase mutant with high thermal stability and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827847A (en) * | 2012-07-25 | 2012-12-19 | 上海凯宝药业股份有限公司 | Codon-optimized 7 beta-hydroxy steroid dehydrogenase gene |
CN102827848A (en) * | 2012-07-25 | 2012-12-19 | 上海凯宝药业股份有限公司 | 7alpha-hydroxyl steroid dehydrogenase gene optimized by codon |
-
2016
- 2016-09-22 CN CN201610844106.9A patent/CN106282138B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827847A (en) * | 2012-07-25 | 2012-12-19 | 上海凯宝药业股份有限公司 | Codon-optimized 7 beta-hydroxy steroid dehydrogenase gene |
CN102827848A (en) * | 2012-07-25 | 2012-12-19 | 上海凯宝药业股份有限公司 | 7alpha-hydroxyl steroid dehydrogenase gene optimized by codon |
Non-Patent Citations (1)
Title |
---|
DESHUAI LOU ET AL: "The three-dimensional structure of Clostridium absonum 7α-hydroxysteroid dehydrogenase: new insights into the conserved arginines for NADP(H) recognition", 《SCIENTIFIC REPORTS》 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106701707B (en) * | 2017-01-05 | 2019-07-26 | 重庆大学 | 7alpha-Hydroxysteroid dehydrogenase gene S1-a-1 |
CN106701708A (en) * | 2017-01-05 | 2017-05-24 | 重庆大学 | New 7alpha-hydroxysteroid dehydrogenase gene Y1-a-1 |
CN106701707A (en) * | 2017-01-05 | 2017-05-24 | 重庆大学 | Gene S1-a-1 of novel 7 alpha-HSDH (hydroxysteroid dehydrogenase) |
CN107058250A (en) * | 2017-01-05 | 2017-08-18 | 重庆大学 | 7 new beta hydroxysteroid dehydrogenase gene Y1 b 1 |
CN106676079A (en) * | 2017-01-05 | 2017-05-17 | 重庆大学 | Novel 7alpha-hydroxysteroid dehydrogenase gene S1-a-2 |
CN106701708B (en) * | 2017-01-05 | 2019-07-26 | 重庆大学 | 7alpha-Hydroxysteroid dehydrogenase gene Y1-a-1 |
CN107058250B (en) * | 2017-01-05 | 2019-07-26 | 重庆大学 | 7beta-Hydroxysteroid dehydrogenase gene Y1-b-1 |
CN106676079B (en) * | 2017-01-05 | 2019-07-26 | 重庆大学 | 7alpha-Hydroxysteroid dehydrogenase gene S1-a-2 |
CN107841489A (en) * | 2017-11-14 | 2018-03-27 | 重庆大学 | The α hydroxysteroid dehydrogenase mutant K179M of Clostridium sardiniense 7 |
CN108034643A (en) * | 2017-12-18 | 2018-05-15 | 重庆大学 | 7alpha-Hydroxysteroid dehydrogenase and its encoding gene and application |
CN110387360A (en) * | 2019-06-18 | 2019-10-29 | 华东理工大学 | Hydroxysteroid dehydrogenase and its application in synthesis ursodeoxycholic acid precursors |
CN110387360B (en) * | 2019-06-18 | 2021-12-28 | 华东理工大学 | Hydroxysteroid dehydrogenase and application thereof in synthesis of ursodeoxycholic acid precursor |
CN112725212A (en) * | 2021-01-15 | 2021-04-30 | 江南大学 | Recombinant yeast chassis cell transformation for efficiently converting chenodeoxycholic acid, recombinant strain construction and application |
CN112852652A (en) * | 2021-01-15 | 2021-05-28 | 江南大学 | Recombinant yeast strain for efficiently converting chenodeoxycholic acid to synthesize ursodeoxycholic acid, construction and application |
CN113430183A (en) * | 2021-08-16 | 2021-09-24 | 重庆大学 | Mutants of 7 alpha-hydroxysteroid dehydrogenase St-2-2T15G, T15S and T15A |
CN113430183B (en) * | 2021-08-16 | 2022-08-23 | 重庆大学 | Mutants of 7 alpha-hydroxysteroid dehydrogenase St-2-2T15G, T15S and T15A |
CN114250205A (en) * | 2021-12-28 | 2022-03-29 | 宋建芳 | 7 alpha-hydroxysteroid dehydrogenase mutant with high thermal stability and application thereof |
CN114250205B (en) * | 2021-12-28 | 2022-11-11 | 宋建芳 | 7 alpha-hydroxysteroid dehydrogenase mutant with high thermal stability and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN106282138B (en) | 2019-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106282138A (en) | Clostridium sardiniense 7 α hydroxysteroid dehydrogenase mutant T145S | |
Watson et al. | Unusual ribulose 1, 5-bisphosphate carboxylase/oxygenase of anoxic Archaea | |
Jia et al. | Properties of a novel thermostable glucose isomerase mined from Thermus oshimai and its application to preparation of high fructose corn syrup | |
CN106434582B (en) | Clostridium sardiniense 7alpha-Hydroxysteroid dehydrogenase mutant R194A | |
Pereira et al. | Structural and biochemical characterization of the early and late enzymes in the lignin β-aryl ether cleavage pathway from Sphingobium sp. SYK-6 | |
Altaş et al. | Heterologous production of extreme alkaline thermostable NAD+-dependent formate dehydrogenase with wide-range pH activity from Myceliophthora thermophila | |
CN107841489B (en) | Clostridium sardinieri 7 α -hydroxysteroid dehydrogenase mutant K179M | |
Weaver et al. | Crystal structures of native and recombinant yeast fumarase | |
Inoue et al. | Type 1 Cu structure of blue nitrite reductase from Alcaligenes xylosoxidans GIFU 1051 at 2.05 Å resolution: comparison of blue and green nitrite reductases | |
Zhang et al. | Exploring a highly D-galactose specific L-arabinose isomerase from Bifidobacterium adolescentis for D-tagatose production | |
Finnegan et al. | Structural and kinetic studies on the Ser101Ala variant of choline oxidase: catalysis by compromise | |
Uemura et al. | The catalytic mechanism of decarboxylative hydroxylation of salicylate hydroxylase revealed by crystal structure analysis at 2.5 Å resolution | |
Jin et al. | Enhanced catalytic efficiency and thermostability of glucose isomerase from Thermoanaerobacter ethanolicus via site-directed mutagenesis | |
Qin et al. | Refolding of a novel cholesterol oxidase from Pimelobacter simplex reveals dehydrogenation activity | |
CN114250205B (en) | 7 alpha-hydroxysteroid dehydrogenase mutant with high thermal stability and application thereof | |
CN107058250B (en) | 7beta-Hydroxysteroid dehydrogenase gene Y1-b-1 | |
Otagiri et al. | Structural basis for chiral substrate recognition by two 2, 3-butanediol dehydrogenases | |
CN107858337A (en) | A kind of heat-resisting mutant lipase and preparation method and application | |
Ishikawa et al. | The first crystal structure of L-threonine dehydrogenase | |
JP2017108740A (en) | Modified meso-diaminopimelic acid dehydrogenase | |
CN106701707A (en) | Gene S1-a-1 of novel 7 alpha-HSDH (hydroxysteroid dehydrogenase) | |
CN109355265A (en) | A kind of carbonyl reduction enzyme mutant mut-AcCR (I147V/G152L) and its application and encoding gene | |
WO2024146119A1 (en) | Obtaining d-amino acid transaminase mutant on the basis of supercomputing aiding and use thereof | |
Toyama et al. | Molecular cloning and structural analysis of quinohemoprotein alcohol dehydrogenase ADH-IIG from Pseudomonas putida HK5 | |
KR101222126B1 (en) | Thiolase with Improved Activity and Method of Producing Biobutanol Using the Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |